- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to the Biostage Q3 2022 Conference Call. At this time, all participants are in a listen-only mode.

As a reminder, this conference is being recorded. It is now my pleasure to introduce your host today, Joe Damasio, Chief Financial Officer. sir. proceed Please

Joe Damasio

is This Good Joe morning. Damasio.

call Green, David the today is Interim Chief me our Executive On with Officer.

discussion make Before I company's our the let me we turn it over forward-looking to statements. forward-looking that constitute statements David, review today, statements. may In

and forward-looking our results and statements, materially differ Form any year results as for annual projected Any those report may be have uncertainties, including ended from risks the in related XXXX, our to future our filings. estimates subsequent other upon our on the including and estimates performance to and public at relied our we and representing as December those previously should actual represent Our what due day. activities, detailed XX, in XX-K of today not

everyone currently hence in our financial which we to to I any and Events and filings like will be period in related material, or call, included our the call. our not presented Form in we website be relation of the available information statistical quiet required remind questions Investor press the in any will taking Section under in archived release, would legally not are SX Presentations. Additionally, the that on and and are

over David. Now I will turn it to

David Green

Thank Biostage you, quarterly to this matters. Joe for and welcome conference discuss related call everyone to earnings and

enable new Biostage new treat disease such tubes as such patches. esophagus are holes use that extension QX. Tissue third and reflux Joe this from October the turn hollow These Biostage’s include, well new Joe? XXXX. gastero-esophageal intestine. it Biostage review technology on is on the XXXX, as or of esophagus first, damage are over as of Patch. technology to which gastero-intestinal quarter to patent the technology to for Officer, X, as our Damasio GERD, or as a other and from damage or in the the US Let's the parts as to disease, now first tract new the highlights XXXX protects about talk fistulas to results received hired August of Chief narrowings stomach expects this Joe Biostage which known XX, as business second we This such Financial I'll financial the strictures of

Joe Damasio

want our Thank you, cover results. quarter I highlights briefly to the of third financial

million Our include or compensation figures quarter non-cash share-based and $X.X $X.XX share basic of expenses. per million net approximately diluted was loss for September per approximately charges XX, ‘XX. $X.X ended the depreciation and Those

fund had use $X we hand no Based million million debt. current the approximately quarter. our of operating pass ending plan, expenditure for for in current had operations we XXXX, XX, I operating on cash expenses September during be of on remarks. the of and We capital sufficient XXXX. our our into cash David will As expect approximately second that quarter $X.X to to back cash requirements and

David Green

a for you all today. And Biostage participation goodbye. Thank look to Thank success. making you forward we and your

Operator

teleconference. does conclude today's This

participation. time. may You And lines you thank for your your disconnect this at

Operator

[Operator Instructions]

Harvard Apparatus Regenerative Technology (HRGN) 15 Nov 222022 Q3 Earnings call transcript